Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence

Brown, Darron R.; Joura, Elmar A.; Yen, Glorian P.; Kothari, Smita; Luxembourg, Alain; Saah, Alfred J.; Walia, Anuj; Pérez, Gonzalo; Khoury, Hanane; Badgley, Danielle; Stanley, Margaret

doi:10.1016/j.vaccine.2020.11.076

Cited by 33 publications

(26 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the first report using observational epidemiologic data to support evidence of cross‐protection of 4vHPV on cervical precancers, showing a 51% reduction in HPV31‐CIN2+ and a 57% reduction in HPV31‐CIN3+. This is consistent with data from 4vHPV vaccine trials, which also showed a decline in HPV31‐CIN2+ 15 . Additionally, cross‐protection for prevalence of cervicovaginal HPV31 infection has been observed in epidemiologic studies, 28,29 including a recent U.S. study that documented a 37% decline in HPV31 among screened 20 to 24‐year‐olds 30 .…”

Section: Discussionsupporting

confidence: 86%

“…This is consistent with data from 4vHPV vaccine trials, which also showed a decline in HPV31-CIN2+ . 15 Additionally, cross-protection for prevalence of cervicovaginal HPV31 infection has been observed in epidemiologic studies, 28,29 including a recent U.S. study that documented a 37% decline in HPV31 among screened 20 to 24-year-olds. 30 In a meta-analysis of population-level impact of HPV vaccination programs worldwide, cross-protection for HPV31/33/45 was observed, particularly in programs that used the bivalent vaccine.…”

Section: Discussionmentioning

confidence: 98%

“…9 Understanding type-specific CIN2+ incidence could help to further specify vaccine impact on CIN2+. It could also enable evaluation of cross-protection against nonvaccine types, which has been suggested in several studies of HPV prevalence, 15 and type replacement by nonvaccine high-risk HPV types, which has been inconsistently reported. 16 Neither cross-protection nor type replacement has been evaluated in observational epidemiologic studies of CIN2+, although cross-protection from 4vHPV vaccination was observed in a clinical trial.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016

Gargano

McClung

Lewis

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Declines in cervical intraepithelial neoplasia grades 2 to 3 and adenocarcinoma in situ (CIN2+) observed among young women suggest impact from human papillomavirus (HPV) vaccination. To further evaluate vaccine impact including cross-protection and type replacement, we described high-risk (HR)-HPV type-specific cervical precancer incidence rates among women aged 20 to 39 years, 2008 to 2016. We analyzed cross-sectional population-based data on 18 344 cases of CIN2+ from a 5-site surveillance system. Diagnostic specimens were tested for individual HPV types, including 14 HR-HPV types (

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016

Gargano

McClung

Lewis

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…HPV vaccination has shown to reduce the HPV prevalence and HPV-related diseases, in countries with high vaccine coverage. [22][23][24] Evidence suggests that the bivalent and quadrivalent vaccines induce cross-protection against the not targeted types HPV31/33/45. 23 24 In Costa Rica, quadrivalent HPV vaccination was introduced in 2019 targeting girls aged 10 years, thus our estimates of prevalence/incidence of HPV infection did not benefit from the indirect protection by the vaccine-eligible cohorts of the vaccination programme.…”

Section: Discussionmentioning

confidence: 99%

“…The strengths of the present study include the large sample size and the use of well-validated HPV detection/genotyping methods 12. HPV vaccination has shown to reduce the HPV prevalence and HPV-related diseases, in countries with high vaccine coverage 22–24. Evidence suggests that the bivalent and quadrivalent vaccines induce cross-protection against the not targeted types HPV31/33/45 23 24.…”

Section: Discussionmentioning

confidence: 99%

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

et al. 2022

View full text Add to dashboard Cite

IntroductionHuman papillomavirus (HPV) vaccines protect against incident HPV infections, which cause cervical cancer.ObjectivesWe estimated the prevalence and incidence of HPV infections in young adult women to understand the impact of an HPV vaccination programme in this population.MethodsWe collected cervical specimens from 6322 unvaccinated women, aged 18–37 years, who participated in the Costa Rica Vaccine Trial and its long-term follow-up. Women were followed for (median) 4.8 years and had (median) 4.0 study visits. Cervical specimens were tested for the presence/absence of 25 HPV genotypes. For each age band, we estimated the percentage of women with 1+ prevalent or 1+ incident HPV infections using generalised estimating equations. We also estimated the prevalence and incidence of HPV as a function of time since first sexual intercourse (FSI).ResultsThe model estimated HPV incident infections peaked at 28.0% (95% CI 25.3% to 30.9%) at age 20 years then steadily declined to 11.8% (95% CI 7.6% to 17.8%) at age 37 years. Incident oncogenic HPV infections (HPV16/18/31/33/35/39/45/51/52/56/58/59) peaked and then declined from 20.3% (95% CI 17.9% to 22.9%) to 7.7% (95% CI 4.4% to 13.1%); HPV16/18 declined from 6.4% (95% CI 5.1% to 8.1%) to 1.1% (95% CI 0.33% to 3.6%) and HPV31/33/45/52/58 declined from 11.0% (95% CI 9.3% to 13.1%) to 4.5% (95% CI 2.2% to 8.9%) over the same ages. The percentage of women with 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable (HPV16/18, HPV31/33/45, HPV31/33/45/52/58, and HPV6/11) types peaked <1 year after FSI and steadily declined with increasing time since FSI (p for trends <0.001). We observed similar patterns for model estimated HPV prevalences.ConclusionYoung adult women may benefit from HPV vaccination if newly acquired vaccine-preventable oncogenic infections lead to cervical precancer and cancer. HPV vaccination targeting this population may provide additional opportunities for primary prevention.Trial registration numberNCT00128661.

show abstract

Green Nanotechnology Approaches in Vaccinology: Advantages and Disadvantages in Biomedical Sciences

Dey,

Singh

2023

Nanovaccinology

View full text Add to dashboard Cite

Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence

Cited by 33 publications

References 85 publications

HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016

HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

Green Nanotechnology Approaches in Vaccinology: Advantages and Disadvantages in Biomedical Sciences

Contact Info

Product

Resources

About